Management of cancer pain: ESMO clinical practice guidelines

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Ripamonti, C I ^a   Santini, D ^b   Maranzano, E ^c   Berti, M ^d   Roila, F ^c  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c S MARIA HOSPITAL   (Italy)

^d UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BUPRENORPHINE; CODEINE; DENOSUMAB; DEXAMETHASONE; FENTANYL; FENTANYL CITRATE; GABAPENTIN; HYDROCODONE; HYDROMORPHONE; LIDOCAINE; METHADONE; MEXILETINE; MORPHINE; MORPHINE SULFATE; NALOXONE; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OXYCODONE; PARACETAMOL; PLACEBO; TRAMADOL; ZOLEDRONIC ACID;

ALLODYNIA; ANOREXIA; ARTICLE; ASTHENIA; BONE METASTASIS; BONE PAIN; BREAKTHROUGH PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER STAGING; CELIAC PLEXUS; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISTRESS SYNDROME; DOCTOR PATIENT RELATION; DOSE RESPONSE; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG OVERDOSE; DRUG SAFETY; DRUG WITHDRAWAL; HALLUCINATION; HUMAN; HYPERALGESIA; HYPERCALCEMIA; INCIDENCE; INVASIVE PROCEDURE; METASTATIC SPINAL CORD COMPRESSION; MYOCLONUS; NAUSEA AND VOMITING; NERVE BLOCK; NEUROPATHIC PAIN; PAIN ASSESSMENT; PAIN THRESHOLD; PATIENT ASSESSMENT; PATIENT EDUCATION; PERIPHERAL NERVE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PRURITUS; SPINAL CORD COMPRESSION; TERMINAL DISEASE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VERTIGO;

EID: 84866597131     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds233     Document Type: Article

References (120)

1. Van den Beuken-van Everdingen MHJ, De Rijke JM, Kessels AG et al. Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-1449.
2. Sun V, Borneman T, Piper B et al. Barriers to pain assessment and management in cancer survivorship. J Cancer Surviv 2008; 2: 65-71.
3. Burton AW, Fanciullo GJ, Beasley RD et al. Chronic pain in cancer survivor: a new frontier. Pain Med 2007; 8: 189-198.
4. Deandrea S, Montanari M, Moja L et al. Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 2008; 19(12): 1985-1991.
5. Costantini M, Ripamonti C, Beccaro M et al. Prevalence, distress, management and relief of pain during the last three months of cancer patients' life. Resultsof an Italian mortality follow-back survey. Ann Oncol 2009; 20: 729-735.
6. Breivik H, Cherny N, Collett F et al. Cancer-related pain: a pan European survey of prevalence, treatment, and patient attitudes. Ann Oncol 2009; 20: 1420-1433.
7. Higginson IJ, Murtagh F. Cancer pain epidemiology. In Bruera E, Portenoy RK (eds), Cancer Pain. Assessment and Management. Cambridge University Press 2010; 3: 37-52.
8. Morselli M, Bandieri E, Zanin R et al. Pain and emotional distress in leukaemia patients at diagnosis. Leuk Res 2009; 34(2): e67-e68.
9. Apolone G, Corli O, Caraceni A et al. Pattern and quality of care of cancer pain management. Results from the Cancer Pain Outcome Research Study Group. Br J Cancer 2009; 100: 1566-1574.
10. Portenoy RK, Koh M. Cancer pain syndromes. In Bruera E, Portenoy RK (eds), Cancer Pain. Assessment and Management. Cambridge University Press 2010; 4: 53-88.
11. Frankish H. 15 million new cancer cases per year by 2020, says WHO. Lancet 2003; 361: 1278.
12. Caraceni A, Cherny N, Fainsinger R et al. The Steering Committee of the EAPC Research Network. Pain measurement tools and methods in clinical research in palliative care: recommendations of an expert working group of the European Association of Palliative Care. J Pain Symptom Manage 2002; 23: 239-255.
13. Larue F, Colleau SM, Brasseur L et al. Multicentre study of cancer pain and its treatment in France. BMJ 1995; 310: 1034-1037.
14. Kaasalainen S. Pain assessment in older adults with dementhia using behavioural observation methods in clinical practice. J Gerontol Nurs 2007; 33: 6-10.
15. Gordon DB, Dahl JL, Miaskowski C et al. American pain society recommendations for improving the quality of acute and cancer painmanagement: American Pain Society Quality of Care Task Force. Arch InternMed 2005; 165: 1574-1580.
16. Van Herk R, van Dijk M, Baar FPM et al. Observational scales for pain assessment in older adults with cognitive impairments or communication difficulties. Nurs Res 2007; 56(1): 34-43.
17. American Geriatrics Society Panel on Persistent Pain in Older Persons. The management of persistent pain in older persons. J Am Geriatr Soc 2002; 50 (6): S205-S224.
18. Zaza C, Baine N. Cancer pain and psychosocial factors: a critical review of the literature. J Pain Symptom Manage 2002; 24(5): 526-542.
19. Reid CM, Gooberman Hill R, Hanks GW. Opioid analgesics for cancer pain: symptom control for the living or comfort for the dying? A qualitative study to investigate the factors influencing the decision to accept morphine for pain caused by cancer. Ann Oncol 2008; 19(1): 44-48.
20. De Wit R, van Dam F, Zandbelt L et al. A pain education program for chronic cancer pain patients: follow-up results from a randomized controlled trial. Pain 1997; 73(1): 55-69.
21. World Health Organization. Cancer Pain Relief, 2nd edition. Geneva: World Health Organization 1996.
22. National Comprehensive Cancer Network. (NCCN) Clinical Practice Guideline in Oncology. Adult Cancer Pain V.I. 2009.
23. Hanks GW, De Conno F, Ripamonti C et al. Morphine in cancer pain: modes of administration. BMJ 1996; 312: 823-826.
24. Hanks GW, De Conno F, Cherny N et al. of the Expert Working Group of the Research Network of the European Association for Palliative Care. Morphine and alternative opioids in cancer pain. Br J Cancer 2001; 84(5): 587-593.
25. Scottish Intercollegiate Guidelines Network. Control of Pain in Adults with Cancer. A National Clinical Guideline. Edinburgh, Scotland: SIGN-Scottish Intercollegiate Guidelines Network, November 2008.
26. Caraceni A, Hanks G, Kaasa S et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13: 58-68.
27. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain 1990; 41: 273-281.
28. World Health Organization. Cancer Pain Relief. Geneva: World Health Organization 1986.
29. Wallenstein S, Heidrich Gr, Kaiko R. Clinical evaluation of mild analgesics: the measurement of clinical pain. Br J Clin Pharmacol 1980; 10(Suppl 2): 319S-327S.
30. Littman G, Walker B, Schneider B. Reassessment of verbal and visual analog ratings in analgesic studies. Clin Pharmacol Therap 1985; 38(1): 16-23.
31. Serlin RC, Mendoza TR, Nakamura Y. When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 1995; 61: 277-284.
32. Lussier D, Portenoy RK. Adjuvant analgesic drugs. In Bruera E, Higginson IJ, Ripamonti C, von Gunten C (eds), Textbook of Palliative Medicine. London: Edward Arnold Publishers 2006; 402-414.
33. Paice JA, Ferrell B. The management of cancer pain. CA Cancer J Clin 2011; 61: 157-182.
34. McNicol E, Strassels S, Gouds L et al. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD005180. DOI: 10.1002/14651858. CD005180.
35. Stockler M, Vardy J, Pillai A. Acetominophen (Paracetamol) improves pain and well-being in people with advanced cancer already receiving a strong opioid regimen: a randomized, double-blind, placebo-controlled cross-over trial. J Clin Oncol 2004; 22(16): 3389-3394.
36. Nabal M, Librada S, Redondo S et al. The role of paracetamol and nonsteroidal anti-inflammatory drugs in addition to WHO Step III opioids in the control of pain in advanced cancer. A systematic review of the literature. Palliat Med 2012; 26(4): 305-312.
37. Joint Formulary Committee. British National Formulary, 55th edition. London: British Medical Association and Royal Pharmaceutical Society of Great Britain, 2007.
38. European Medicines Agency. Public statement: European Medicines Agency announces regulatory action on COX-2 inhibitors (EMEA/62838/2005). http://www.ema.europa.eu/docs/en_GB/document_library/Public_statement/2009/11/WC500014818.pdf.
39. Grond S, Radbruch L. Weak opioids. Meta-analysis for the therapy of chronic pain. Der Schmer 1998; 12: 142-155.
40. Arbaiza D, Vidal O. Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study. Clin Drug Investig 2007; 27(1): 75-83.
41. Rodriguez RF, Castillo JM, Castillo MP et al. Hydrocodone/acetaminophen and tramadol chloridrate combination tablets for the management of chronic cancer pain: a doubl-blind comparative trial. Clin J Pain 2008; 24(1): 1-4.
42. Rodriguez RF, Bravo LE, Castro F et al. Incidence of weak opioids adverse events in the management of cancer pain: a double-blind comparative trial. J Palliat Med 2007; 10: 56-60.
43. Eisenberg E, Berkey C, Carr DB et al. Efficacy and safety of nonsteroidal antinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994; 12: 2756-2765.
44. Agency for Healthcare Research and Quality. Evidence Report/Technology Assessment: Number 35. 2001.
45. Ventafridda V. A validation study of the WHO method for cancer pain relief. Cancer 1987; 59: 851-856.
46. Marinangeli F, Ciccozzi A, Leonardis M et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004; 27: 409-416.
47. Maltoni M, Scarpi E, Modonesi C et al. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer 2005; 13: 888-894.
48. Mercadante S, Porzio G, Ferrera P et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006; 31: 242-247.
49. Tassinari D, Drudi F, Rosati M et al. The second step of the analgesic ladder and oral tramadol in the treatment of mild to moderate cancer pain: a systematic review. Palliat Med 2011; 25(5): 410-423.
50. Cherny NI, Baselga J, De Conno F. Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/ EAPC Opioid policy initiative. Ann Oncol 2010; 21: 615-626.
51. Ripamonti C, Bareggi C. Pharmacology of opioid analgesia: clinical principles. In Bruera E, Portenoy RK (eds), Cancer Pain. Assessment and Management.Cambridge: Cambridge University Press 2010; 11: 195-229.
52. Bandieri E, Chirarolanza A, Luppi M et al. Prescription of opioids in Italy: everything but the morphine. Ann Oncol (letters to the editor) 2009; 20: 961-962.
53. World Health Organization. Model List of Essential Drugs (EDL). Geneva, Switzerland: World Health Organization 2007.
54. Hanks GW, Hoskin PJ, Aherne GW et al. Explanation for potency of oral morphine on repeated dosage? Lancet 1987; ii: 723-725.
55. Kaiko RF. The therapeutic equivalence of IM and PO administration of morphine -1:3 or 1:6. J Palliat Care 1988; 4: 64-66.
56. Boger RH. Renal impairment: a challenge for opioid treatment? The role of buprenorphine. Palliat Med 2006; 20: s17-s23.
57. King S, Forbes K, Hanks GW et al. A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med 2011; 25: 525-552.
58. Ripamonti C, Groff L, Brunelli C et al. Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio? J Clin Oncol 1998; 16: 3216-3221.
59. Mercadante S, Casuccio A, Groff L et al. Switching from morphine to methadone to improve analgesia and tolerability in cancer patients. A prospective study. J Clin Oncol 2001; 19(11): 2898-2904.
60. Dale O, Moksnes K, Kaasa S. Europena Palliative Care Research Collaborative pain guidelines. Opioid switching to improve analgesia or reduce side effects. A systematic review. Palliat Med 2010; 25(5): 494-503.
61. Ripamonti C, Bandieri E. Cancer pain. Crit Rev Oncol Hematol 2009; 70: 145-149.
62. Harris JT, Suresh Kumar K, Rajagopal MR. Intravenous morphine for rapid control of severe cancer pain. Palliat Med 2003; 17: 248-256.
63. Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine. An evidence-based report. J Clin Oncol 2001; 19: 2542-2554.
64. Stone P, Minton O. European Palliative Care Research collaborative pain guidelines. Central side-effects management: what is the evidence to support best practice in the management of sedation, cognitive impairment and myoclonus? Palliat Med 2011; 25: 431-441.
65. Candy B, Jones L, Goodman ML et al. Laxatives or methylnaltrexone for the management of constipation in palliative care patients. Cochrane Database Syst Rev 2011; 1: CD003448.
66. Ahmedzai SH, Nauck F, Bar-Sela G et al. A randomized, double-blind, activecontrolled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain. Palliat Med 2012; 26(1): 50-60.
67. Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med 2011; 25: 442-453.
68. Vignaroli E, Bennett MI, Nekolaichuk C et al. Strategic pain management: the identification and development of the International Association for Hospice and Palliative Care (IAHPC) Opioid Essential prescription package. J Palliat Med 2012; 15(2): 186-191.
69. Haugen DF, Hjermstad MJ, Hagen N et al. Assessment and classification of cancer Breakthrough pain: a systematic literature review. Pain 2010; 149(3): 476-482.
70. Greco MT, Corli O, Montanari M et al. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients. Results from the cancer pain outcome research and study group. Clin J Pain 2011; 27: 9-18.
71. Mercadante S, Radbruch I, Caraceni A et al. Episodic breakthrough pain: consensus conference of an export working group of the European Association for Palliative Care. Cancer 2002; 94: 832-839.
72. Mercadante S, Villari P, Ferrera P et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodicbreakthrough pain. Br J Cancer 2007; 12: 1828-1833.
73. Zeppetella G, Riberio MDC. Opioids for the management of breakthrough episodic pain in cancer patients. Cochrane data base of systematic reviews (on line) 2006; 1: CDOO4311.
74. Vissers D, Stam W, Nolte T et al. Efficacy of intranasal fentanyl spray vs other opioids for breakthrough pain in cancer. Curr Med Res Opin 2010; 26: 1037-1045.
75. Portenoy RK, Burton AW, Gabrail N et al; the Fentanyl Pectin Nasal Spray 043 Study Group. A multicenter, placebo-controlled, double-blind, multiple-crossover study of fentanyl pectin nasal spray (FPNS) in the treatment of breakthrough cancer pain. Pain 2010; 151: 617-624.
76. Coluzzi PH, Schwartzberg L, Conroy JD et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate OTFC and morphine sulphate immediate release MSIR. Pain 2001; 1-2: 123-130.
77. Mercadante S, Radbruch L, Davies AN et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain- an open label, randomized, cross-over trial. Curr Med Res Opin 2009; 25(11): 2805-2815.
78. Davies A, Sitte T, Elsner F et al. Consistency of efficacy, patient acceptabilityand nasal tolerability of fentanyl pectin nasal spray compared with immediaterelease morphine sulphate in breakthrough cancer pain. J Pain Symptom Manage 2011; 41: 358-366.
79. Uberall MA, Muller-Schwefe Gerhard HH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin 2011; 27(7): 1385-1394.
80. Harris K, Li K, Flynn C et al. Worst, average or current pain in the brief pain inventory: which should be used to calculate the response to palliativeradiotherapy in patients with bone metastases? Clin Oncol 2007; 19: 523-527.
81. Chow E, Harris K, Fan G et al. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol 2007; 10: 1423-1436.
82. Lutz S, Berk L, Chang E et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79: 965-976.
83. Saghal A, Larson DA, Chang EL. Stereotactic Body radiosurgery for spinal metastases: a critical review. Int J Radiat Oncol Biol Phys 2008; 71: 652-665.
84. Loblaw DA, Perry J, Chambers A et al. Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative's Neuro-Oncology Disease Site Group. J Clin Oncol 2005; 23: 2028-2037.
85. Holt T, Hoskin P, Maranzano E et al. Malignant epidural spinal cord compression: the role of external beam radiotherapy. Curr Opin Support Palliat Care 2012; 6: 103-108.
86. Maranzano E, Bellavita R, Rossi R et al. Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial. J Clin Oncol 2005; 23: 3358-3365.
87. Maranzano E, Trippa F, Casale M et al. 8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial. Radiother Oncol 2009; 93: 174-179.
88. Patchell RA, Tibbs PA, Regine WF et al. Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: a randomised trial. Lancet 2005; 366: 643-648.
89. Roqué I, Figuls M, Zapata-Martinez MJ et al. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev 2011; (7): CD003347.
90. Han SH, de Klerk JM, Tan S et al. The PLACORHeN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study. J Nucl Med 2002; 43(9): 1150-1156.
91. Wong R, Wiffen PJ. Bisphosphonates for relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002; (2): CD002068.
92. Ripamonti C, Maniezzo M, Campa T et al. Decreased occurrence of osteonecrosis of the jaws (ONJs) after implementation of dental preventive measure in solid tumors treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Italy. Ann Oncol 2009; 20: 137-145.
93. Dimopoulos MA, Kastritis E, Bamia C et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117-120.
94. Stopeck A, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. Clin Oncol 2010; 28(35): 5132-5139.
95. Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29(9): 1125-1132.
96. Fizazi K, Carducci M, Smith M et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377(9768): 813-822.
97. Cleeland CS et al. Pain outcomes in a Randomized Phase 3 Clinical Trial of Denosumab vs Zoledronic Acid (ZA) in Patients with Solid Tumors and Bone Metastases. Ann Oncol 2010; 21: 8s (abstract 1248P).
98. Van Poznak CH, Temin S, Yee GC et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bonemodifying agents in metastatic breast cancer. J Clin Oncol 2011; 29(9): 1221-1227.
99. Garcia de Paredes ML, del Moral Gonzalez F, Martinez del Prado P et al. First evidence of oncologic neuropathic pain prevalence after screening 8615 cancer patients. Results of the on study. Ann Oncol 2011; 22: 924-930.
100. Tan T, Barry P, Reken S et al. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 2010; 340: c1079.
101. Saarto T, Wiffen P. Antidepressants for neuropathic pain (Cochrane Review). In The Cochrane Library 2007.
102. Wiffen P, McQuay H, Edwards J et al. Gabapentin for acute and chronic pain. Cochrane Database of Systematic Reviews 2011, Issue 3. Art. No.: CD005452. DOI: 10.1002/14651858.CD005452.pub2.
103. Wiffen P, Collins S, McQuay H et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD001133. DOI: 10.1002/14651858.CD001133.pub3.
104. Challapalli V, Tremont-Lukats IW, McNicol ED et al. Systemic administration of local anesthetic agents to relieve neuropathic pain. Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD003345. DOI: 10.1002/ 14651858.CD003345.pub2.
105. Roosa DA, Turnerb SL, O'Brienc PC et al. Randomized trial of 8 Gy in 1 versus 20 Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases, Trans-Tasman Radiation Oncology Group, TROG 96.05. Radiother Oncol 2005; 75: 54-63.
106. Simpson KH. Interventional techniques for pain management in palliative care. Medicine 2011; 39(11): 645-647.
107. Vainio A, Tigerstedt I. Opioid treatment for radiating cancer pain: oral administration vs epidural techniques. Acta Anaesthesiol Scand 1988; 32: 179-180.
108. Kalso E, Heiskanen T, Rantio M et al. Epidural and subcutaneous morphine in the management of cancer pain: a double-blind cross-over study. Pain 1996; 67: 443-449.
109. Myers J, Chan V, Jarvis V et al. Intraspinal techniques for pain management in cancer patients: a systematic review. Support Care Cancer 2010; 18: 137-149.
110. Ballantyne J, Carwood C. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD005178. DOI: 10.1002/14651858.CD005178.
111. Smith TJ, Staats PS, Deer T et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol 2002; 20(19): 4040-4049
112. Ripamonti C, Brunelli C. Randomized Clinical Trial of an Implantable Drug Delivery System compared with comprehensive Medical management for refractory cancer pain: impact on Pain, Drug-Related Toxicity, and survival. J Clin Oncol 2003; 21(14): 2801-2802.
113. Deer T, Krames ES, Hassenbush SJ et al. Polyanalgesic Consensus Conference 2007: Recommendations for the management of pain by intrathecal (Intraspinal) drug delivery: report of an interdisciplinary expert panel. Neuromodulation 2007; 10(2): 300-328.
114. Vissers KCP, Besse K, Wagemans M et al. Pain in patients with cancer. Pain Pract 2011; 11(5): 453-475.
115. Chambers WA. Nerve blocks in palliative care. Br J Anaesth 2008; 101: 95-100.
116. Wyse JM, Carone M, Paquin SC et al. Randomized, double-blind, controlled trial of early endoscopic Ultrasound-Guided Celiac Plexus Neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable cancer. J Clin Oncol 2011; 29: 3541-3546.
117. Puli SR, Reddy JB, Bechtold ML et al. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain. A meta-analysis and systematic review. Dig Dis Sci 2009; 54: 2330-2337.
118. Arcidiacono PG, Calori G, Carrara S et al. Celiac plexus block for pancreatic cancer pain in adults. Cochrane Database of Systematic Reviews 2011. Issue 3. Art. No.: CD007519. DOI: 10.1002/14651858.CD007519.pub2.
119. Cherny NJ, Chang V, Frager G et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995; 76: 1283-1293.
120. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990; 47: 639-664.